Talaris Therapeutics

OverviewSuggest Edit

Talaris Therapeutics is a cell therapy company developing an method of allogeneic hematopoietic stem cell transplantation. Its Facilitated Allo-HSCT Therapy can prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines, also known as chronic immunosuppression. The company aims to  transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders.
TypePublic
Founded2002
HQLouisville, KY, US
Websitetalaristx.com

Latest Updates

Employees (est.) (Mar 2021)82
Job Openings4
Share Price (Sept 2021)$15.7(+15%)
Cybersecurity ratingAMore

Key People/Management at Talaris Therapeutics

Scott Requadt

Scott Requadt

Chief Executive Officer
Suzanne Ildstad

Suzanne Ildstad

Chief Scientific Officer and Founder
Nancy Krieger

Nancy Krieger

Chief Medical Officer
Michael Zdanowski

Michael Zdanowski

Chief Technology Officer
Andrew Beavis

Andrew Beavis

Senior Director of Quality Control
Devin Blass

Devin Blass

Vice President of Technical Operations
Show more

Talaris Therapeutics Office Locations

Talaris Therapeutics has offices in Louisville and Wellesley
Louisville, KY, US (HQ)
570 S Preston St
Louisville, KY, US
201 E Jefferson St #110B
Wellesley, MA, US
93 Worcester St #120
Show all (3)

Talaris Therapeutics Financials and Metrics

Talaris Therapeutics Revenue

USD

Net income (Q1, 2021)

(9.3m)

EBIT (Q1, 2021)

(9.0m)

Market capitalization (8-Sept-2021)

565.0m

Closing stock price (8-Sept-2021)

15.7

Cash (31-Mar-2021)

9.9m
Talaris Therapeutics's current market capitalization is $565 m.
USDQ1, 2021

General and administrative expense

2.5m

R&D expense

6.5m

Operating expense total

9.0m

EBIT

(9.0m)
USDQ1, 2021

Cash

9.9m

Prepaid Expenses

2.7m

Current Assets

142.8m

PP&E

2.1m
USDQ1, 2021

Net Income

(9.3m)

Depreciation and Amortization

135.0k

Accounts Payable

1.0k

Cash From Operating Activities

(9.0m)
USDQ1, 2021

Financial Leverage

-3.1 x
Show all financial metrics

Talaris Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Talaris Therapeutics Online and Social Media Presence

Embed Graph

Talaris Therapeutics News and Updates

Talaris Therapeutics to Participate at Two Upcoming Virtual Investor Conferences

BOSTON and LOUISVILLE, Ky., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and cer…

Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update

BOSTON and LOUISVILLE, Ky., June 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and cert…

Talaris Therapeutics Announces Upcoming Presentations on FCR001 at the Virtual 2021 American Transplant Congress

BOSTON and LOUISVILLE, Ky., June 03, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and cert…

Talaris Therapeutics Announces Closing of Initial Public Offering

BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and cert…

Talaris Therapeutics Announces Pricing of Initial Public Offering

BOSTON and LOUISVILLE, Ky., May 06, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-m…

Talaris Therapeutics Blogs

Talaris Therapeutics Appoints Mary Kay Fenton as Chief Financial Officer

BOSTON, Mass., and LOUISVILLE, Ky., March 4, 2021 – Talaris Therapeutics, Inc., a late- clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant b…

Talaris Therapeutics Appoints Four Vice Presidents in Areas of Strategic Importance

BOSTON, Mass., and LOUISVILLE, Ky., February 25, 2021 – Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, ce…

Talaris Therapeutics Adds Two Experienced Biotechnology Executives to its Board of Directors

BOSTON, Mass., and LOUISVILLE, Ky., January 20, 2021– Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced the appointment of Sapna Srivast…

Talaris Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

BOSTON, Mass., and LOUISVILLE, Ky., January 8, 2021 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, is scheduled to virtually present at the 39th An…

Talaris Therapeutics Expands Leadership Team with Appointments of Accomplished Executives in Manufacturing, Portfolio Strategy and Clinical Operations

BOSTON, Mass., and LOUISVILLE, Ky., November 12, 2020 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced the expansion of its senior le…

Talaris Therapeutics lands $115M in venture capital funding

Louisville Business First: The is the second time in about 18 months that this company has turned heads with its capital raises. FULL STORY The post Talaris Therapeutics lands $115M in venture capital funding appeared first on Talaris.
Show more

Talaris Therapeutics Frequently Asked Questions

  • When was Talaris Therapeutics founded?

    Talaris Therapeutics was founded in 2002.

  • Who are Talaris Therapeutics key executives?

    Talaris Therapeutics's key executives are Scott Requadt, Suzanne Ildstad and Nancy Krieger.

  • How many employees does Talaris Therapeutics have?

    Talaris Therapeutics has 82 employees.

  • Who are Talaris Therapeutics competitors?

    Competitors of Talaris Therapeutics include Fulcrum Therapeutics, AmacaThera and CinCor Pharma.

  • Where is Talaris Therapeutics headquarters?

    Talaris Therapeutics headquarters is located at 570 S Preston St, Louisville.

  • Where are Talaris Therapeutics offices?

    Talaris Therapeutics has offices in Louisville and Wellesley.

  • How many offices does Talaris Therapeutics have?

    Talaris Therapeutics has 3 offices.